We use some essential cookies to make this website work.
We鈥檇 like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Approval of a change to the licence of Comirnaty COVID-19 vaccine will enable thawing and re-labelling of the vaccine outside of the NHS
No one should stop taking valproate without advice from their healthcare professional
皇冠体育app Medicines and Healthcare products Regulatory Agency (MHRA) has today (30 January 2024) approved the medicine momelotinib (Omjjara) to treat the symptoms experienced by adult myelofibrosis patients who have moderate or se鈥�
皇冠体育app Medicines and Healthcare products Regulatory Agency (MHRA) has today (29 January 2024) approved the medicine Rezzayo (rezafungin) to treat a fungal infection called invasive candidiasis.
In partnership with other global regulators, IRP is expected to further help bring life-saving new medicines to UK patients.
IRP is expected to further help bringing life-saving new medicines to UK patients from 1 January 2024
Casgevy (exagamglogene autotemcel) is based on the innovative gene-editing tool CRISPR, which won its inventors the Nobel Prize in 2020
For the first time, 2- to 5-year-old patients with a certain type of cystic fibrosis could access cystic fibrosis drugs Kaftrio and Kalydeco.
For the first time in the UK, obese patients and people who are overweight with weight-related health problems could now have access to Mounjaro, currently used for Type 2 diabetes, to help manage their weight and support we鈥�
Patients with a certain type of advanced or spreading non-small cell lung cancer (NSCLC) could access a new cancer therapy to help treat their condition.
Patients with severe alopecia areata (patchy hair loss) could access a new medicine to help treat their condition.
Patients with recurring lymphoma, or who have not responded to prior treatments, could access a new bispecific antibody therapy to help treat their condition.聽
皇冠体育app vaccine was approved after it was found to meet the MHRA鈥檚 standards of safety, quality and effectiveness.
皇冠体育app vaccine was approved after it was found to meet the UK regulator's standards of safety, quality and effectiveness
皇冠体育app new COVID-19 vaccine from SK Chemicals, has been authorised after meeting the MHRA鈥檚 required safety, quality and effectiveness standards.
皇冠体育app government, NHS England and the pharmaceutical industry will begin negotiating the successor to the voluntary scheme for branded medicines, pricing and access (VPAS).
First published during the 2022 to 2024 Sunak Conservative government
皇冠体育app Comirnaty COVID vaccine has met the MHRA鈥檚 required safety, quality and effectiveness standards to be authorised for use in this age group
It is the first treatment approved by the UK regulator that has been made possible through the Access Consortium 鈥楴ew Active Substance Work Sharing Initiative鈥�.
Use of the Moderna COVID-19 vaccine or 鈥楽pikevax鈥� has been approved for 6 to 11s after meeting the required safety, quality and effectiveness standards
皇冠体育app government announces its intention to introduce a licensing regime for non-surgical cosmetic procedures such as Botox and fillers.
First published during the 2019 to 2022 Johnson Conservative government
Don鈥檛 include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we鈥檇 like to know more about your visit today. .